Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 2
2006 1
2007 4
2008 3
2009 3
2013 5
2014 2
2015 1
2016 3
2017 4
2018 6
2019 7
2020 9
2021 14
2022 16
2023 12
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

90 results

Results by year

Filters applied: . Clear all
Page 1
TumorFusions: an integrative resource for cancer-associated transcript fusions.
Hu X, Wang Q, Tang M, Barthel F, Amin S, Yoshihara K, Lang FM, Martinez-Ledesma E, Lee SH, Zheng S, Verhaak RGW. Hu X, et al. Among authors: tang m. Nucleic Acids Res. 2018 Jan 4;46(D1):D1144-D1149. doi: 10.1093/nar/gkx1018. Nucleic Acids Res. 2018. PMID: 29099951 Free PMC article.
Gene fusion represents a class of molecular aberrations in cancer and has been exploited for therapeutic purposes. In this paper we describe TumorFusions, a data portal that catalogues 20 731 gene fusions detected in 9966 well characterized cancer samples and 648 normal sp …
Gene fusion represents a class of molecular aberrations in cancer and has been exploited for therapeutic purposes. In this paper we d …
KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer.
Alam H, Tang M, Maitituoheti M, Dhar SS, Kumar M, Han CY, Ambati CR, Amin SB, Gu B, Chen TY, Lin YH, Chen J, Muller FL, Putluri N, Flores ER, DeMayo FJ, Baseler L, Rai K, Lee MG. Alam H, et al. Among authors: tang m. Cancer Cell. 2020 Apr 13;37(4):599-617.e7. doi: 10.1016/j.ccell.2020.03.005. Epub 2020 Apr 2. Cancer Cell. 2020. PMID: 32243837 Free PMC article.
These findings indicate that KMT2D is a lung tumor suppressor and that KMT2D deficiency confers a therapeutic vulnerability to glycolytic inhibitors....
These findings indicate that KMT2D is a lung tumor suppressor and that KMT2D deficiency confers a therapeutic vulnerability to glycol …
Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma.
Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, Hess JM, Uzunangelov V, Walter V, Danilova L, Lichtenberg TM, Kucherlapati M, Kimes PK, Tang M, Penson A, Babur O, Akbani R, Bristow CA, Hoadley KA, Iype L, Chang MT; TCGA Research Network; Cherniack AD, Benz C, Mills GB, Verhaak RGW, Griewank KG, Felau I, Zenklusen JC, Gershenwald JE, Schoenfield L, Lazar AJ, Abdel-Rahman MH, Roman-Roman S, Stern MH, Cebulla CM, Williams MD, Jager MJ, Coupland SE, Esmaeli B, Kandoth C, Woodman SE. Robertson AG, et al. Among authors: tang m. Cancer Cell. 2017 Aug 14;32(2):204-220.e15. doi: 10.1016/j.ccell.2017.07.003. Cancer Cell. 2017. PMID: 28810145 Free PMC article.
Downregulation of G protein-coupled receptor kinase 4 protects against kidney ischemia-reperfusion injury.
Yang D, Tang M, Zhang M, Ren H, Li X, Zhang Z, He B, Peng S, Wang W, Fang D, Song Y, Xiong Y, Liu ZZ, Liang L, Shi W, Fu C, Hu Y, Jose PA, Zhou L, Han Y, Zeng C. Yang D, et al. Among authors: tang m. Kidney Int. 2023 Apr;103(4):719-734. doi: 10.1016/j.kint.2022.12.023. Epub 2023 Jan 18. Kidney Int. 2023. PMID: 36669643
Thus, our findings reveal that GRK4 triggers necroptosis and aggravates kidney ischemia/reperfusion injury, and its downregulation may provide a promising therapeutic strategy for kidney protection....
Thus, our findings reveal that GRK4 triggers necroptosis and aggravates kidney ischemia/reperfusion injury, and its downregulation may provi …
SMYD2 inhibition-mediated hypomethylation of Ku70 contributes to impaired nonhomologous end joining repair and antitumor immunity.
Tang M, Chen G, Tu B, Hu Z, Huang Y, DuFort CC, Wan X, Mao Z, Liu Y, Zhu WG, Lu W. Tang M, et al. Sci Adv. 2023 Jun 16;9(24):eade6624. doi: 10.1126/sciadv.ade6624. Epub 2023 Jun 14. Sci Adv. 2023. PMID: 37315132 Free PMC article.
Our study reveals an unidentified role of SMYD2 in regulating NHEJ pathway and innate immune responses, suggesting that SMYD2 is a promising therapeutic target for cancer treatment....
Our study reveals an unidentified role of SMYD2 in regulating NHEJ pathway and innate immune responses, suggesting that SMYD2 is a promising …
Single-cell multimodal glioma analyses identify epigenetic regulators of cellular plasticity and environmental stress response.
Johnson KC, Anderson KJ, Courtois ET, Gujar AD, Barthel FP, Varn FS, Luo D, Seignon M, Yi E, Kim H, Estecio MRH, Zhao D, Tang M, Navin NE, Maurya R, Ngan CY, Verburg N, de Witt Hamer PC, Bulsara K, Samuels ML, Das S, Robson P, Verhaak RGW. Johnson KC, et al. Among authors: tang m. Nat Genet. 2021 Oct;53(10):1456-1468. doi: 10.1038/s41588-021-00926-8. Epub 2021 Sep 30. Nat Genet. 2021. PMID: 34594038 Free PMC article.
Glioma intratumoral heterogeneity enables adaptation to challenging microenvironments and contributes to therapeutic resistance. We integrated 914 single-cell DNA methylomes, 55,284 single-cell transcriptomes and bulk multi-omic profiles across 11 adult IDH mutant or IDH w …
Glioma intratumoral heterogeneity enables adaptation to challenging microenvironments and contributes to therapeutic resistance. We i …
SIRT7: a sentinel of genome stability.
Tang M, Tang H, Tu B, Zhu WG. Tang M, et al. Open Biol. 2021 Jun;11(6):210047. doi: 10.1098/rsob.210047. Epub 2021 Jun 16. Open Biol. 2021. PMID: 34129782 Free PMC article. Review.
Tumor Hypoxia Drives Genomic Instability.
Tang M, Bolderson E, O'Byrne KJ, Richard DJ. Tang M, et al. Front Cell Dev Biol. 2021 Mar 16;9:626229. doi: 10.3389/fcell.2021.626229. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 33796526 Free PMC article. Review.
As a common characteristic of cancer, hypoxia is associated with poor prognosis due to enhanced tumor malignancy and therapeutic resistance. The enhanced tumor aggressiveness stems at least partially from hypoxia-induced genomic instability. ...
As a common characteristic of cancer, hypoxia is associated with poor prognosis due to enhanced tumor malignancy and therapeutic resi …
Targeted Therapies for Kirsten Rat Sarcoma (KRAS) G12C Mutant Metastatic Non-Small-Cell Lung Cancers.
O'Leary C, Murphy G, Yeung Y, Tang M, Jain V, O'Leary CG. O'Leary C, et al. Among authors: tang m. Cancers (Basel). 2023 Nov 25;15(23):5582. doi: 10.3390/cancers15235582. Cancers (Basel). 2023. PMID: 38067288 Free PMC article. Review.
Though classically difficult to target, recently developed KRAS G12C inhibitors (sotorasib and adagrasib) have now overcome this therapeutic hurdle. We discuss the evidence for these medications, their pitfalls and adverse effects, as well as future directions in this spac …
Though classically difficult to target, recently developed KRAS G12C inhibitors (sotorasib and adagrasib) have now overcome this therapeu …
The ARID1A-METTL3-m6A axis ensures effective RNase H1-mediated resolution of R-loops and genome stability.
Zhang J, Chen F, Tang M, Xu W, Tian Y, Liu Z, Shu Y, Yang H, Zhu Q, Lu X, Peng B, Liu X, Xu X, Gullerova M, Zhu WG. Zhang J, et al. Among authors: tang m. Cell Rep. 2024 Feb 27;43(2):113779. doi: 10.1016/j.celrep.2024.113779. Epub 2024 Feb 13. Cell Rep. 2024. PMID: 38358891 Free article.
Given the association of high ARID1A levels with resistance to genotoxic therapies in patients, these findings open avenues for exploring potential therapeutic strategies for cancers with ARID1A abnormalities....
Given the association of high ARID1A levels with resistance to genotoxic therapies in patients, these findings open avenues for exploring po …
90 results